Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Non-Current Deferred Tax Liability: 2022-2025

  • InMed Pharmaceuticals' Non-Current Deferred Tax Liability was N/A to $20,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $20,000, marking a year-over-year change of. This contributed to the annual value of $20,000 for FY2025, which is N/A change from last year.
  • Per InMed Pharmaceuticals' latest filing, its Non-Current Deferred Tax Liability stood at $20,000 for Q2 2025, which was down 90.53% from $211,266 recorded in Q2 2023.
  • InMed Pharmaceuticals' Non-Current Deferred Tax Liability's 5-year high stood at $211,266 during Q2 2023, with a 5-year trough of $20,000 in Q2 2025.
  • In the last 2 years, InMed Pharmaceuticals' Non-Current Deferred Tax Liability had a median value of $115,633 in 2023 and averaged $115,633.
  • Data for InMed Pharmaceuticals' Non-Current Deferred Tax Liability shows a peak YoY skyrocketed of 194.22% (in 2023) over the last 5 years.
  • Over the past 3 years, InMed Pharmaceuticals' Non-Current Deferred Tax Liability (Quarterly) stood at $71,806 in 2022, then spiked by 194.22% to $211,266 in 2023, then reached $20,000 in 2025.
  • Its Non-Current Deferred Tax Liability stands at $20,000 for Q2 2025, versus $211,266 for Q2 2023 and $71,806 for Q2 2022.